A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer.
A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES
100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的临床结果
登录后查看更多信息
100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的转化医学
登录后查看更多信息
100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的专利(医药)
登录后查看更多信息
1
项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的文献(医药)
2005-10-01·Current opinion in molecular therapeutics
Technology evaluation: Onyvax-P, Onyvax.
Review
作者: Böhmer, Torsten ; Doehn, Christian ; Jocham, Dieter
Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.
100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的药物交易